2020
CTIM-18. DENDRITIC CELL VACCINATION IN CONJUNCTION WITH ADJUVANT TLR-3 AGONIST ADMINISTRATION ENHANCES PRO-INFLAMMATORY IMMUNE RESPONSES AND IS ASSOCIATED WITH EXTENDED SURVIVAL IN MALIGNANT GLIOMA PATIENTS
Chavez C, Everson R, Orpilla J, Lee A, Khattab S, Antonios J, Salazar A, Cloughesy T, Liau L, Sun L, Hugo W, Prins R. CTIM-18. DENDRITIC CELL VACCINATION IN CONJUNCTION WITH ADJUVANT TLR-3 AGONIST ADMINISTRATION ENHANCES PRO-INFLAMMATORY IMMUNE RESPONSES AND IS ASSOCIATED WITH EXTENDED SURVIVAL IN MALIGNANT GLIOMA PATIENTS. Neuro-Oncology 2020, 22: ii36-ii37. PMCID: PMC7650313, DOI: 10.1093/neuonc/noaa215.152.Peer-Reviewed Original ResearchPatient's peripheral blood mononuclear cellsMalignant glioma patientsToll-like receptorsImmune responsePoly ICLCDendritic cellsClinical trialsTumor lysate-pulsed DCGlioma patientsTLR-3Lysate-pulsed DCPeripheral blood mononuclear cellsPhase II clinical trialTLR-7 agonistDendritic cell vaccinesPro-inflammatory immune responseWHO grade IIITLR-3 agonistIncreased expression of pro-inflammatory genesMGMT methylation statusBlood mononuclear cellsII clinical trialsExpression of pro-inflammatory genesPro-inflammatory responseExpression of pro-inflammatory factors
2018
ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION
Antonios J, Everson R, Soto H, Khattab S, Bethel J, Sun M, Mochizuki A, Lee A, Odesa S, Billingslea-Yoon E, Moughon D, Wang A, Cloughesy T, Prins R, Liau L. ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION. Neuro-Oncology 2018, 20: vi10-vi10. PMCID: PMC6216157, DOI: 10.1093/neuonc/noy148.034.Peer-Reviewed Original ResearchToll-like receptorsMedian survivalDendritic cellsDC vaccinesGrade III or IV gliomaTumor lysate-pulsed DCGlioblastoma multiformePoly ICLCAutologous tumor lysateDC vaccine treatmentLysate-pulsed DCMGMT methylated tumorsMGMT unmethylated tumorsTLR-7 agonistPeripheral blood mononuclear cellsGrade III tumorsTLR-3 agonistIncreased overall survivalGrade IV tumorsBlood mononuclear cellsModulate immune responsesIII tumorsIV tumorsMethylated tumorsOverall survival
2017
NIMG-36. DELINEATION OF IMMUNE RESPONSES AFTER IMMUNOTHERAPY IN GLIOBLASTOMA USING PET AND MRI
Soto H, Antonios J, Everson R, Moughon D, Wang A, Orpilla J, Radu C, Ellingson B, Lee J, Cloughesy T, Phelps M, Czernin J, Liau L, Prins R. NIMG-36. DELINEATION OF IMMUNE RESPONSES AFTER IMMUNOTHERAPY IN GLIOBLASTOMA USING PET AND MRI. Neuro-Oncology 2017, 19: vi149-vi150. PMCID: PMC5692246, DOI: 10.1093/neuonc/nox168.611.Peer-Reviewed Original ResearchPD-1Dendritic cellsMAb blockadeContrast enhancementHost anti-tumor immune responseTreated with dendritic cellsAnti-tumor immune responseInflammatory responseClinical management of patientsDendritic cell vaccinesTumor-infiltrating lymphocytesSyngeneic immunocompetent miceTreated with immunotherapyCo-registration of PETSecondary lymphoid organsContrast-enhanced MRIManagement of patientsProbe uptakePET probeImmune inflammatory responseNon-invasive modalityNon-invasive imaging techniqueImmunocompetent micePre-contrast T1Cell vaccineDetection of immune responses after immunotherapy in glioblastoma using PET and MRI
Antonios J, Soto H, Everson R, Moughon D, Wang A, Orpilla J, Radu C, Ellingson B, Lee J, Cloughesy T, Phelps M, Czernin J, Liau L, Prins R. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proceedings Of The National Academy Of Sciences Of The United States Of America 2017, 114: 10220-10225. PMID: 28874539, PMCID: PMC5617282, DOI: 10.1073/pnas.1706689114.Peer-Reviewed Original ResearchConceptsPD-1Dendritic cellsMAb blockadeTumor lysate-pulsed DC vaccineHost antitumor immune responseTreated with dendritic cellsImmune responseDetection of immune responsesClinical management of patientsPET probeAntitumor immune responseTumor-infiltrating lymphocytesSyngeneic immunocompetent miceContrast enhancementSecondary lymphoid organsContrast-enhanced MRIManagement of patientsProbe uptakeNoninvasive imaging techniquesImmune inflammatory responseDC vaccinesImmunocompetent miceIntracranial tumorsImaging techniquesMalignant gliomasImmunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
Antonios J, Soto H, Everson R, Moughon D, Orpilla J, Shin N, Sedighim S, Treger J, Odesa S, Tucker A, Yong W, Li G, Cloughesy T, Liau L, Prins R. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro-Oncology 2017, 19: 796-807. PMID: 28115578, PMCID: PMC5464463, DOI: 10.1093/neuonc/now287.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalB7-H1 AntigenCancer VaccinesFemaleGlioblastomaHumansLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLMyeloid CellsProgrammed Cell Death 1 ReceptorReceptor, Macrophage Colony-Stimulating FactorTumor Cells, CulturedTumor MicroenvironmentXenograft Model Antitumor AssaysConceptsTumor-infiltrating myeloid cellsAdaptive immune resistancePD-1 mAbCSF-1RiPD-1Immune resistancePD-L1Dendritic cellsMyeloid cellsColony stimulating factor 1 receptor inhibitorAnti-PD-1 monoclonal antibodyResponse to dendritic cellsIn vivo preclinical modelsPD-1 blockadePD-L1 expressionTumor-infiltrating lymphocytesPD-1/PD-L1Measured overall survivalSignificant survival benefitDevelopment of immune resistanceCytolysis in vitroLong-term survivalDC vaccinesTIL infiltrationOverall survivalChapter 12 Dendritic Cell Therapy for Brain Tumors
Everson R, Antonios J, Tucker A, Liau L. Chapter 12 Dendritic Cell Therapy for Brain Tumors. 2017, 301-321. DOI: 10.1016/b978-0-12-802420-1.00012-0.Peer-Reviewed Original ResearchDC therapyDendritic cellsClinical trialsEvidence of immune responsesImmune responseLimitations of current treatment optionsTreatment of malignant gliomasDendritic cell therapyAntitumor immune responseAntigen presenting abilityCurrent treatment optionsDevelopment of alternative modalitiesDC vaccinesActive immunotherapyProlonged survivalMalignant gliomasPreclinical modelsTreatment optionsTumor cellsCell therapyClinical effectsVaccine formulationsBrain tumorsImmune systemBrain parenchyma
2016
IMST-56. TUMOR LYSATE-PULSED DC VACCINATION INDUCES NEOANTIGEN-SPECIFIC T CELL RESPONSES
Everson R, Shin N, Antonios J, Soto H, Tucker A, Zaretsky J, Orpilla J, Rathe S, Popescu F, Largaespada D, Liau L, Prins R. IMST-56. TUMOR LYSATE-PULSED DC VACCINATION INDUCES NEOANTIGEN-SPECIFIC T CELL RESPONSES. Neuro-Oncology 2016, 18: vi99-vi99. DOI: 10.1093/neuonc/now212.412.Peer-Reviewed Original ResearchAutologous tumor lysateTumor-infiltrating lymphocytesTumor-specific mutationsDC vaccinesDendritic cellsCD8+ T cell responsesEnhanced T cell infiltrationTumor-infiltrating lymphocyte culturesImmune responseIntracranial GL261 gliomasT cell infiltrationT cell responsesPhase III trialsTreatment groupsRelevant target antigensMurine glioma cell lineDC therapyTCR clonotypesTumor lysateGL261 gliomasIII trialsNeoantigen peptidesOriginal tumorGlioma cell linesLymphocytic infiltrationTMIC-16. TUMOR-INFILTRATING MYELOID CELLS MEDIATE ADAPTIVE IMMUNE RESISTANCE IN GLIOBLASTOMA
Antonios J, Soto H, Everson R, Orpilla J, Shin N, Moughon D, Sedighim S, Treger J, Odesa S, Tucker A, Yong W, Cloughesy T, Prins R, Liau L. TMIC-16. TUMOR-INFILTRATING MYELOID CELLS MEDIATE ADAPTIVE IMMUNE RESISTANCE IN GLIOBLASTOMA. Neuro-Oncology 2016, 18: vi203-vi203. DOI: 10.1093/neuonc/now212.856.Peer-Reviewed Original ResearchPD-1 mAbPD-1/PD-L1PD-1Immune responseDendritic cellsMAb blockadeColony stimulating factor 1 receptor inhibitorTumor lysate-pulsed dendritic cellsProgrammed death-1/ligand-1Cytolysis of tumor cellsMurine in vivo studiesDC vaccine treatmentAdaptive immune resistanceExpressed PD-L1Cell populationsVaccine treatmentTreatment to miceDominant mediatorIn vitro cytotoxicity assayTIL populationsPD-L1TIL infiltrationGL261 tumorsReceptor inhibitorsTumor microenvironment
2015
Dendritic cell immunotherapy for brain tumors
Antonios J, Everson R, Liau L. Dendritic cell immunotherapy for brain tumors. Journal Of Neuro-Oncology 2015, 123: 425-432. PMID: 26037466, DOI: 10.1007/s11060-015-1830-1.Peer-Reviewed Original ResearchConceptsDendritic cellsPatient-derived dendritic cellsDestruction of malignant cellsDendritic cell immunotherapyGlioma treatmentPre-clinical modelsCell immunotherapyDC vaccinesTreatment of gliomaActive immunotherapyProlonged survivalMalignant cellsImmunological targetsPatient-specific treatmentClinical trialsImmune responseTherapeutic approachesBrain tumorsBrain parenchymaGliomaImmunotherapyTreatmentBrainCellsImmunosuppression